Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more

Recent & Breaking News (NDAQ:SLRX)

Salarius Pharmaceuticals and Nationwide Children's Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire September 30, 2021

Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas

GlobeNewswire September 28, 2021

Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference

GlobeNewswire September 27, 2021

Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership

GlobeNewswire September 22, 2021

Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index

GlobeNewswire September 20, 2021

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

GlobeNewswire September 15, 2021

Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 8, 2021

Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational

GlobeNewswire August 12, 2021

Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

GlobeNewswire August 5, 2021

Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results

GlobeNewswire July 29, 2021

Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit

GlobeNewswire July 14, 2021

Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

GlobeNewswire July 13, 2021

Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

GlobeNewswire July 9, 2021

REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

GlobeNewswire June 17, 2021

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

GlobeNewswire June 15, 2021

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

GlobeNewswire June 10, 2021

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat's Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

GlobeNewswire June 7, 2021

Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

GlobeNewswire May 19, 2021

Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights

GlobeNewswire May 12, 2021

Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results

GlobeNewswire May 5, 2021